|
|
 |
|
Viewing report
|
|
|
|
Pricing, Reimbursement, and Market Access in the BRIC-MT Markets
Decision Resources, Inc, Sep 2011
The BRIC-MT countries - Brazil, Russia, India, China, Mexico, and Turkey - are the cornerstone of multinational pharmaceutical companies’ emerging markets strategies. Favorable economic, demographic, and healthcare-sector dynamics have enticed these multinational companies (MNCs) with opportunities for success unrivaled in the mature markets of the developed world. This report investigates the pharmaceutical pricing and reimbursement environments in the BRIC-MT countries, explores the differences and similarities among these diverse markets, and discusses strategies and opportunities for pharmaceutical companies in emerging markets.
Questions answered in this report:
- Emerging markets—particularly the BRIC-MT countries—have beckoned the international pharmaceutical industry with opportunities based on burgeoning economies, dynamic healthcare systems, and substantial unmet medical needs. What are the projected pharmaceutical sales growth rates for each marketplace? What is the current and projected population in these markets, and how do these affect the size of their pharmaceutical markets? What market dynamics and competitive landscape exist in each of these countries?
- Many BRIC-MT governments are investing heavily in healthcare sector development. What is the nature of the healthcare infrastructure in these markets? What areas have governments prioritized for investment? In which BRIC-MT countries has increased healthcare expenditure benefitted the international pharmaceutical industry? Do MNCs suffer when domestic firms benefit from government efforts to develop the local pharmaceutical sector?
- Cost-containment is a priority in BRIC-MT countries as payers struggle to ensure access for their citizens. What is the mechanism for achieving drug approvals and reimbursement in the BRIC-MT markets? How are drugs paid for in these markets? How do price-setting mechanisms in the BRIC-MT markets relate to prices in the mature markets worldwide?
- As MNCs have brought their portfolios of brands to BRIC-MT markets, they have learned that the dynamics in these countries are very different from those in mature markets. What kind of intellectual property protection is in place? How open are these governments to the participation of MNCs? What country-specific dynamics inform savvy MNCs’ market-appropriate strategies?
Scope:
Markets covered: Brazil, Russia, India, China, Mexico, and Turkey.
Socioeconomic and demographic backgrounds: Projections of total populations and age distributions; key economic indicators; investment in healthcare.
Organization and funding of healthcare systems: Healthcare reforms; expenditures; key providers and purchasers; access to health insurance and prescription drug coverage.
Intellectual property protection: Reforms adopted in recent years; duration of exclusivity periods; challenges facing international brands.
Pharmaceutical pricing: Procedures for setting prices; pharmacy and wholesaler margins; use of external reference pricing.
Admission to reimbursement: Bodies involved in reimbursement decision making; reimbursement procedures; data requirements for manufacturer dossiers; reimbursement rates.
Cost-containment: Reference pricing; pharmaceutical budgets; measures to promote greater use of generics.
Exhibits: 24 tables/figures describing socioeconomic trends, healthcare sector dynamics, pharmaceutical market projections, insurance scheme details, and pharmaceutical pricing policies.
|
|
|
|
